Portal de Periódicos da CAPES

Current and proposed biologic markers in prostate cancer

1992; Wiley; Volume: 50; Issue: S16H Linguagem: Inglês

10.1002/jcb.240501214

1097-4644

David G. Bostwick, Rodolfo Montironi, Raymond Nagle, Thomas G. Pretlow, Gary J. Miller, Thomas M. Wheeler, Jonathan I. Epstein, Wael Sakr,

Colorectal Cancer Treatments and Studies

Journal of Cellular BiochemistryVolume 50, Issue S16H p. 65-67 Invited CommentFree Access Current and proposed biologic markers in prostate cancer David G. Bostwick M.D., David G. Bostwick M.D. Dept. of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905Search for more papers by this authorRodolfo Montironi M.D., Rodolfo Montironi M.D. Department of Pathology, University of Ancona, Ancona, ItalySearch for more papers by this authorRaymond Nagle M.D., Ph.D., Raymond Nagle M.D., Ph.D. Department of Pathology, University of Arizona, Tucson, AZ 85724Search for more papers by this authorThomas Pretlow M.D., Thomas Pretlow M.D. Department of Pathology, Case Western Reserve University, Cleveland, OH 44106Search for more papers by this authorGary Miller M.D, Ph.D., Gary Miller M.D, Ph.D. Department of Pathology, University of Colorado, Denver, CO 80262Search for more papers by this authorThomas Wheeler M.D., Thomas Wheeler M.D. Department of Pathology, Baylor College of Medicine, Houston, TX 77030Search for more papers by this authorJonathan Epstein M.D., Jonathan Epstein M.D. Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21205Search for more papers by this authorWael Sakr M.D., Wael Sakr M.D. Department of Pathology, Harper Hospital, Detroit, MI 48201Search for more papers by this author David G. Bostwick M.D., David G. Bostwick M.D. Dept. of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905Search for more papers by this authorRodolfo Montironi M.D., Rodolfo Montironi M.D. Department of Pathology, University of Ancona, Ancona, ItalySearch for more papers by this authorRaymond Nagle M.D., Ph.D., Raymond Nagle M.D., Ph.D. Department of Pathology, University of Arizona, Tucson, AZ 85724Search for more papers by this authorThomas Pretlow M.D., Thomas Pretlow M.D. Department of Pathology, Case Western Reserve University, Cleveland, OH 44106Search for more papers by this authorGary Miller M.D, Ph.D., Gary Miller M.D, Ph.D. Department of Pathology, University of Colorado, Denver, CO 80262Search for more papers by this authorThomas Wheeler M.D., Thomas Wheeler M.D. Department of Pathology, Baylor College of Medicine, Houston, TX 77030Search for more papers by this authorJonathan Epstein M.D., Jonathan Epstein M.D. Department of Pathology, Johns Hopkins Hospital, Baltimore, MD 21205Search for more papers by this authorWael Sakr M.D., Wael Sakr M.D. Department of Pathology, Harper Hospital, Detroit, MI 48201Search for more papers by this author First published: 1992 https://doi.org/10.1002/jcb.240501214Citations: 4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Bostwick DG. Graham SD, Npalkov P, Abrahamsson P, di Sant'Agnese PA, Algaba F, Hoisaeter PA, Lee F, Littrup P, Mostofi FK, Denis L, Schroeder F, Murphy GP: Staging of early prostate cancer: A proposed tumor volume-based prognostic index (submitted). 2 Eble JN, Epstein JI: Stage A carcinoma of the prostate. In DG Bostwick (ed): " Pathology of the Prostate." New York: Churchill-Livingstone, 1990, pp 61– 82. 3 McNeal JE, Redwine EA, Freiga FS, Stamey TA: Zonal distribution of prostatic adenocarcinoma. Am J Surg Pathol 12: 897, 1988. 4 Gleason DF: Histologic grading of prostatic carcinoma. In DG Bostwick (ed): " Pathology of the Prostate." New York: Churchill-Livingstone, 1990, pp 83– 93. 5 Bostwick DG: The pathology of early prostate cancer. CA: Cancer J Clin 39: 376– 393, 1989. 6 Bostwick DG, Bose D, Srigley J, Grignon D, Maksem J, van der Kwast T, Humphrey P, Young R: Morphologic criteria for distinguishing atypical adenomatous hyperplasia (adenosis) from well differentiated adenocarcinoma of the prostate (in preparation). 7 Weaver MG, Abdul-Karim FW, Srigley J, Bostwick DG, Ro JY, Ayala AG: Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study. Am J Surg Pathol 16: 62– 68, 1992. 8 Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC: Pathological factors that influence prognosis in stage A prostatic cancer: The influence of extent versus grade. J Urol 125: 516– 521, 1981. 9 Bostwick DG, Eble JN: Variant of prostatic carcinoma. In DG Bostwick (ed): " Pathology of the Prostate." New York: Churchill-Livingstone, 1990, pp 95– 133. 10 Epstein JI, Woodruff JM: Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer 57: 111– 117, 1986. 11 Epstein JI, Lieberman PH: Mucinous adenocarcinoma of the prostate gland. Am J Surg Pathol 9: 299– 306, 1985. 12 Montironi R, Scarpelli M, Sisti S, Braccischi A, Gusella P, Pisani E, Alberti R, Mariuzzi GM: Quantitative analysis of prostatic intraepithelial neoplasia on tissue sections. Anal Quant Cytol Histol 12: 366– 372, 1990. 13 Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS: A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in Stage A2 prostate cancer: A critical analysis. J Urol 142: 1254, 1989. 14 Helpap B: Observations on the number, size and localization of nucleoli in hyperplastic and neoplastic prostatic disease. Histopathology 13: 203– 211, 1988. 15 Sesterhenn IA, Becker RL, Avallolne FA, Mostofi FK, Lin TH, Davis CJ Jr: Image analysis of nucleoli and nucleolar organizerregions in prostatic hyperplasia, PIN and prostatic carcinoma. J Urogenital Pathol 1: 42– 51, 1991. 16 Sadi MV, Barrack ER: Determination of growth factor in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 67: 3065– 3071, 1991. 17 Sarkar F, Sakr F, Sakr W, Drozdowicz S, Sreepathi P, Crissman J: Measurement of cellular proliferation in human prostate by AgNOR, PCNA and SPF. Mod Pathol 5: 59A (abstract), 1992). 18 Helpap B: The biological significance of atypical hyperplasia of the prostate. Virchows Arch (A) 387: 307– 313, 1980. 19 Nemoto R, Hattori K, Uchida K, Shimazui T, Nishijima Y, Koiso K, Harada M: S-phase fraction of human prostate adenocarcinoma studies with in vivo bromodeoxyuridine labeling. Cancer 66: 509– 516, 1990. 20 Badalament RA, O'Toole RV, Young DC, Drago JR: DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 67: 3014– 3023, 1991. 21 Bookstein R, Shew JY, Chen PL, Scully P, Lee WH: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712– 715, 1990. 22 Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A, Schlom J: Expression of ras oncogene p21 in prostate cancer. N Engl J Med 314: 133– 137, 1986. 23 Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CHW, Neal DE: p53, cerbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 47: 496– 499, 1992. 24 Davies P, Eaton CL, France TD, Phillips MEA: Growth factor receptors and oncogene expression in prostate cells. Am J Clin Oncol 11: S1– S7, 1988. 25 Limon J, Lundgren R, Elfving P, Heim S, Kristofferson WF, Mandahl N, Mitelman F: An improved technique for short-term culturing of human prostatic adenocarcinoma tissue for cytogenetic analysis. Cancer Genet Cytogenet 46: 191– 196, 1990. 26 Eaton CL, Davies P, Philips MEA: Growth factor involvement and oncogene expression in prostatic tumors. J Steroid Biochem 30: 341– 345, 1988. 27 di Sant' Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, ant therapeutic implications. Cancer, 1992 (in press). 28 Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907– 923, 1991. 29 McNeal JE, Alroy J, Leav I, Redwine EA, Freiha FS, Stamey TA: Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. Am J Clin Pathol 90: 23– 32, 1988. 30 Boag AH, Young ID: Type IV collagenase expression in prostatic adenocarcinoma. Mod Pathol 5: 51A (abstract), 1992. 31 Doctor VM, Sheth AR, Simha MM, Arbatti NJ, Aaveri JP: Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: Comparison of its distribution in normal, benign, and malignant prostates. Br J Cancer 53: 547– 554, 1986. 32 Beckett ML, Lipfors GB, Haley CL, Schellhammer PF, Wright GL Jr: Monoclonal antibody PD-41 recognizes an antigen restricted to prostate adenocarcinomas. Cancer Res 51: 1326– 1333, 1991. 33 Grignon DJ, Wright C: Glutathione S-Transferase π(GSTπ) expression in prostatic intraepithelial neoplasia (PIN): An immunohistochemical study. 1992 International Symposium on Biology of Prostate, Bethesda, Maryland (abstract)(in press). 34 van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhover CCJ, Mulder E, Boersma W, Trapman J: An drogen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189– 193, 1991. 35 Nagle RB, Brawer MK, Kittelson J, Clark V: Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am j Pathol 138: 119– 128, 1991. 36 McNeal JE, Leav I, Alroy J, Skutelsky E: Differential lectin staining of central and peripheral zones of the prostate and alterations in dysplasia. Am J Clin Pathol 89: 41– 48, 1988. 37 Perlman EJ, Epstein JI: Blood group antigen expression in dysplasia and adenocarcinoma of the prostate. Am J Surg Pathol 14: 810– 818, 1990. 38 McNeal JE, Alroy J, Villers A, Redwine EA, Freiha FS, Stamey TA: Mucinous differentiation in prostatic adenocarcinoma. Hum Pathol 22: 979– 988, 1991. 39 Bigler SA Brawer MK, Deering RE: Neovascularization in carcinoma of the prostate: A quantitative morphometric study. Mod Pathol 5: 50A (abstract), 1992. 40 Fuchs ME, Brawer MK, Rennels MA, Nagle RB: The relationship of basement membrane to histologic grade of human prostatic carcinoma. Mod Pathol 2: 105– 111, 1989. 41 Bologna M, Vicentini C, Festuccia C, Muzi P, Napolitano T, Biordi L, Miano L: Short-term tissue culture of prostatic carcinoma samples provides useful biological parameters related to patient prognosis. Eur Urol 15: 243– 248, 1988. Citing Literature Volume50, IssueS16HSupplement: Chemoprevention of Premalignant and Early Malignant Lesions of the Prostate1992Pages 65-67 ReferencesRelatedInformation